Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy

Pancreatic cancer is the 7th leading cause of cancer death amongst adults in the US and is associated with 6% 5-year overall survival rate for Stage II cancers (1), declining to 3% for patients with Stage III disease. Surgical resection offers the highest chance for remission, with 5-year survival rates of up to 20% (2-5). Unfortunately, many patients present with disease that is not amenable to potentially curative upfront resection (1). After neoadjuvant therapy, some borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) may ultimately undergo a margin negative (R0) resection